WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has implemented an accelerated stock repurchase (ASR) program to repurchase $300 million of common stock, as part of its previously announced authorization from its Board of Directors to repurchase up to $500 million of common stock. The new ASR program will enable the Company to facilitate, on a more timely and cost efficient basis, the repurchase of a substantial number of its shares pursuant to that stock repurchase authorization.
